Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma

Yadav, Vikas LU orcid ; Jena, Manoj Kumar ; Singh, Tejveer ; Kumar, Ravi and Garg, Vivek Kumar (2026) In Frontiers in Oncology 16.
Abstract

Melanoma is the deadliest type of skin cancer, arising from melanocytes, and its global incidence continues to rise. Although multiple somatic mutations contribute towards melanoma development, but the BRAF mutation is the most prevalent. The FDA approval of targeted therapies for BRAF-mutant melanoma greatly increased overall survival in considerable number of patients. However, the majority of patients eventually developed resistance against BRAF inhibitors (BRAFi) and the underlying mechanisms still under explorations. Recent research has revealed that long noncding RNAs (lncRNAs) are closely linked to the development and progression of several malignancies, including melanoma. However, the connection between lncRNA expression... (More)

Melanoma is the deadliest type of skin cancer, arising from melanocytes, and its global incidence continues to rise. Although multiple somatic mutations contribute towards melanoma development, but the BRAF mutation is the most prevalent. The FDA approval of targeted therapies for BRAF-mutant melanoma greatly increased overall survival in considerable number of patients. However, the majority of patients eventually developed resistance against BRAF inhibitors (BRAFi) and the underlying mechanisms still under explorations. Recent research has revealed that long noncding RNAs (lncRNAs) are closely linked to the development and progression of several malignancies, including melanoma. However, the connection between lncRNA expression profiles and acquired resistance to melanoma BRAFi is in the early stages of research. Herein, we present a current summary of the ways by which lncRNAs either restore melanoma cell susceptibility to BRAFi or cause resistance. Additionally, we have also discussed the potential of lncRNAs role as prognostic indicators of response and resistance to BRAFi therapy in melanoma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
BRAF inhibitor, drug resistance, long noncoding RNA, melanoma, metastasis
in
Frontiers in Oncology
volume
16
article number
1757030
publisher
Frontiers Media S. A.
external identifiers
  • pmid:41982244
  • scopus:105041482687
ISSN
2234-943X
DOI
10.3389/fonc.2026.1757030
language
English
LU publication?
yes
id
43203461-b4a2-4680-9b8a-79fb5ccc55cd
date added to LUP
2026-07-02 10:47:26
date last changed
2026-07-03 03:15:47
@article{43203461-b4a2-4680-9b8a-79fb5ccc55cd,
  abstract     = {{<p>Melanoma is the deadliest type of skin cancer, arising from melanocytes, and its global incidence continues to rise. Although multiple somatic mutations contribute towards melanoma development, but the BRAF mutation is the most prevalent. The FDA approval of targeted therapies for BRAF-mutant melanoma greatly increased overall survival in considerable number of patients. However, the majority of patients eventually developed resistance against BRAF inhibitors (BRAFi) and the underlying mechanisms still under explorations. Recent research has revealed that long noncding RNAs (lncRNAs) are closely linked to the development and progression of several malignancies, including melanoma. However, the connection between lncRNA expression profiles and acquired resistance to melanoma BRAFi is in the early stages of research. Herein, we present a current summary of the ways by which lncRNAs either restore melanoma cell susceptibility to BRAFi or cause resistance. Additionally, we have also discussed the potential of lncRNAs role as prognostic indicators of response and resistance to BRAFi therapy in melanoma.</p>}},
  author       = {{Yadav, Vikas and Jena, Manoj Kumar and Singh, Tejveer and Kumar, Ravi and Garg, Vivek Kumar}},
  issn         = {{2234-943X}},
  keywords     = {{BRAF inhibitor; drug resistance; long noncoding RNA; melanoma; metastasis}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Oncology}},
  title        = {{Insight into the emerging role of long non-coding RNAs in BRAF inhibitor resistance in melanoma}},
  url          = {{http://dx.doi.org/10.3389/fonc.2026.1757030}},
  doi          = {{10.3389/fonc.2026.1757030}},
  volume       = {{16}},
  year         = {{2026}},
}